Clinical analysis of 21 patients with interstitial lung disease complicated with lung cancer

Jia-min LI,Qun-ying HONG,Chun-xue BAI

DOI: https://doi.org/10.3969/j.issn.1009-6663.2015.04.008

2015-01-01

Abstract:Objective To investigate the clinical characteristics and treatments of interstitial lung disease as-sociated with lung cancer ( ILD-LC) , and to improve the treatment of the disease. Methods Their clinical charac-teristics, manifestations, laboratory and imaging examinations and treatments of 21 patients with ILD-LC were retro-spectively analyzed. Results 17 out of 21 patients were male, and 4 were female. The age of the patients ranged from 51 to 88 years old, and the median age was 65 years old. 15 of them had a history of smoking. The clinical manifestations mainly included cough, expectoration and dyspnea after exertion. Computed tomography of chest mainly showed stripe and reticular shadow, honeycombing shadow in both lungs with nodule or mass in single lung. The histology types of lung cancer included adenocarcinoma (47. 6%), squamous cell carcinoma (23. 8%) and small cell carcinoma (28. 6%). 3 cases were diagnosed as ILD at first and then lung cancer after follow-up. The level of NSE, CYFRA21-1 and CEA in serum was increased to 100%, 66. 7% and 33. 3% respectively. 18 cases were diagnosed as ILD and lung cancer at the same time. The level of NSE, CYFRA21-1, CEA and SCC in serum was increased to 50%, 55. 6%, 66. 1% and 16. 7% respectively. 15 patients were treated with platinum doublet chemotherapy, 3 patients underwent surgery and 3 patients received best supportive care. Pneumonia occurred in 5 patients during the treatments. Conclusion To make ILD-LC early diagnosis, ILD patients should be followed-up closely. Serum biomarker and chest CT scan may be necessary to be done regularly as a screening method. Pneumonia and acute exacerbation of ILD may easily occur during the treatments. The risks and the benefits of the treatments should be sufficiently assessed.